This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Currie, B. P.
Right arrow Articles by Lemos-Filho, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Currie, B. P.
Right arrow Articles by Lemos-Filho, L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2004, p. 4427-4429, Vol. 48, No. 11
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.11.4427-4429.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Evidence for Biliary Excretion of Vancomycin into Stool during Intravenous Therapy: Potential Implications for Rectal Colonization with Vancomycin-Resistant Enterococci

Brian P. Currie1* and Luciano Lemos-Filho2

Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center,1 Albert Einstein College of Medicine, Bronx, New York2

Received 24 March 2004/ Returned for modification 28 April 2004/ Accepted 11 July 2004

Sixty-three stool samples and five bile samples were prospectively collected from 33 patients receiving intravenous vancomycin therapy and were quantitatively analyzed for vancomycin by a competitive immunoassay. Vancomycin was excreted via bile into the stools of almost all patients at concentrations of 3.3 to 94.8 µg/ml after ≥5 days of a therapy of 1 g every 12 h.

* Corresponding author. Mailing address: Montefiore Medical Center, 111 E. 210th St., Bronx, NY 10467. Phone: (718) 920-6078. Fax: (718) 920-8543. E-mail: bcurrie{at}montefiore.org.

Antimicrobial Agents and Chemotherapy, November 2004, p. 4427-4429, Vol. 48, No. 11
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.11.4427-4429.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Williams, O. M., Spencer, R. C. (2009). The management of Clostridium difficile infection. Br Med Bull 0: ldp021v1-ldp021 [Abstract] [Full Text]  
  • Halsey, J. (2008). Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 65: 705-715 [Abstract] [Full Text]  
  • Cadle, R. M, Mansouri, M. D, Darouiche, R. O (2006). Vancomycin-Induced Elevation of Liver Enzyme Levels. The Annals of Pharmacotherapy 40: 1186-1189 [Abstract] [Full Text]  
  • Pultz, N. J., Stiefel, U., Donskey, C. J. (2005). Effects of Daptomycin, Linezolid, and Vancomycin on Establishment of Intestinal Colonization with Vancomycin-Resistant Enterococci and Extended-Spectrum-{beta}-Lactamase-Producing Klebsiella pneumoniae in Mice. Antimicrob. Agents Chemother. 49: 3513-3516 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»